WO1997030628A1 - Enhanced transdermal transport of fluid using vacuum - Google Patents

Enhanced transdermal transport of fluid using vacuum Download PDF

Info

Publication number
WO1997030628A1
WO1997030628A1 PCT/US1997/002483 US9702483W WO9730628A1 WO 1997030628 A1 WO1997030628 A1 WO 1997030628A1 US 9702483 W US9702483 W US 9702483W WO 9730628 A1 WO9730628 A1 WO 9730628A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
fluid
analyte
glucose
ultrasound
Prior art date
Application number
PCT/US1997/002483
Other languages
French (fr)
Inventor
Eric B. Shain
Tuan A. Elstrom
Thomas G. Schapira
Timothy P. Henning
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to DE69728525T priority Critical patent/DE69728525T2/en
Priority to AT97906647T priority patent/ATE263505T1/en
Priority to JP9530273A priority patent/JP2000505334A/en
Priority to EP97906647A priority patent/EP0886488B1/en
Publication of WO1997030628A1 publication Critical patent/WO1997030628A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/1451Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
    • A61B5/14514Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement

Definitions

  • the present disclosure relates to improved sampling methods for the detection of analytes in a patient's blood. More specifically, the invention is related to the use of vacuum to enhance the transdermal transport of fluids.
  • the ability to accurately measure analytes in the blood, particularly glucose, is important in the management of diseases such as diabetes.
  • Blood glucose levels must be maintained within a narrow range (about 3.5 - 6.5 mM).
  • Glucose levels lower than this range may lead to mental confusion, coma, or death.
  • High glucose levels cause excessive thirst and frequent urination.
  • Sustained hyperglycemia has been linked to several of the complications of diabetes, such as kidney damage, neural damage, and blindness.
  • Blood glucose levels are maintained in many diabetics with routine injections of insulin. Unlike the normal functioning of the body's glucose control systems, injections of insulin incorporate no feedback mechanisms. Controlling glucose levels therefore requires continuous or frequent measurements of blood glucose concentration in order to determine the proper amount and frequency of insulin injections.
  • US Patent 5,161 ,532 uses a pump to draw interstitial fluid from the skin to an integral glucose sensor.
  • This system requires a pump capable of creating suction at a level of about 200-400 mmHg.
  • EP Publication 0 595 237 discloses an analytical device for measuring blood constituents such as glucose, which also requires a suction pump capable of creating suction at a level of about 400 mmHg.
  • Body fluid is also sampled through the skin with a suction pump in EP Publication 0 513 789.
  • Figure 1 shows one embodiment of the invention.
  • Figure 2 shows an additional embodiment of the invention.
  • Figure 3 shows an additional embodiment of the invention.
  • FIG. 4 shows an additional embodiment of the invention.
  • the present invention provides a process of sampling extracellular fluid from the skin of an animal wherein ultrasound is applied to a region of the skin, reduced pressure is applied to the same vicinity of the skin and any fluid which exudes the skin is collected.
  • the application of ultrasound and reduced pressure may be performed either sequentially or simultaneously.
  • a preferred source of ultrasound is a standing wave.
  • a preferred analyte is glucose.
  • the present invention also provides a device for the transdermal sampling of extracellular fluid comprising a means for generating an ultrasonic wave through skin of an animal, means for applying reduced pressure to the external surface of the skin in the vicinity of the ultrasonic wave, and means for collecting fluid that transudates the skin.
  • a preferred device utilizes an ultrasonic standing wave and incorporates an analysis element for the analysis of the fluid collected.
  • a preferred analyte for collection by the device of the invention is glucose.
  • the present invention also provides an improved apparatus for the sampling of extracellular fluid across the skin of animal comprising the application of reduced pressure to the external surface of the skin in the vicinity of the ultrasonic wave.
  • analyte means any chemical or elemental compound of clinical and/or medical, environmental, or industrial significance and for which quantitative or qualitative measurements may be desired. Examples of specific analytes are well known and include analytes of clinical significance such as glucose, hemoglobin, lipids, cholesterol, proteins, etc. Other analytes will be readily apparent to those skilled in the art. A preferred biological compound is glucose.
  • the present disclosure provides an apparatus and method for enhancing the transdermal transport of analytes.
  • an apparatus of the invention generally consists of a sampling device 10 comprising a ultrasonic source 12, a pressure reducing source 14, a pressure boundary 16 which, together with a surface 20 of a body part, contains a sampling region 18, and an analysis device 22.
  • Any ultrasonic source 12 is suitable for use in the present invention.
  • the source is an ultrasonic transducer capable of generating ultrasonic energy at a frequency range suitable for optimum extraction of glucose, e.g., 20 KHz to 1 MHz.
  • the pressure reducing source 14 is capable of reducing pressure in the sampling region 18 to an absolute pressure of about 400 mmHg; a vacuum pump is preferred.
  • the pump is powered by normal movements, such as the self-actuated pump described in U.S. Patent Application Serial Number (not yet available; Atty Docket Number 5845.US.01 , filed 12- 18-95).
  • the pressure boundary 16 maintains a pneumatic seal against the surface 20 of the body, and may be any of a variety of well known materials suitable for this purpose, e.g., adhesive tape or an elastomeric ring.
  • analysis element 22 located adjacent or, as shown in Figure 1 , in contact with sampling region 18.
  • Analysis element 22 is used to determine the presence or amount of at least one analyte of interest and the particular features of analysis element 22 are not critical to the invention.
  • any analyte detection method, sensor, or system suitable for use with the analyte of interest for example optical or electrochemical sensors known in the art, may be used in analysis element 22.
  • An example of a suitable analysis device is an interference-free biosensor such as that described in U.S. Patent Application Serial Number not yet available; Atty Docket Number 5843.US.01 , filed 12- 18-95).
  • the ultrasound source 12 generates ultrasonic energy directed at the body surface 20.
  • the transmission of this ultrasonic energy may be facilitated by the use of a coupling medium (such as a gel) within the sampling region 18.
  • the interaction of the ultrasonic energy with the body surface 20 increases the permeability of the skin at the body surface as described in current scientific literature (Mitragotri et al, J. Pharm. Sci. 84:697-706, 1995).
  • the pressure reducing source 14 reduces the pressure in the sampling region 18 by removing air within the region 18.
  • a coupling medium within the region 18 should not affect the ability of the pressure reducing source 14 to reduce the pressure within the region 18, and may in fact facilitate the pressure reduction by assisting in maintaining a seal between the pressure boundary 16 and the body surface 20. Any coupling medium should as well not interfere with the operation of the analysis device 22.
  • the combination of the enhanced permeability of the skin due to the ultrasonic energy and the pressure difference between the tissue and the sampling region will cause the enhanced flow of body fluid through the body surface 20 into the sampling region, where the concentration of the analyte is measured by the analysis device 22.
  • FIG. 3 A second embodiment of the invention is illustrated in Figure 3.
  • pressure reducing source 14 is in vacuum connection with the pressure boundary 16 and the ultrasound source 12 and the analysis device 22 are contained within the sampling region 18.
  • Such an arrangement facilitates ultrasound transmission, as the ultrasound source 12 may be directly coupled to the body surface 20, if necessary with the local application of a coupling medium such as a gel.
  • This arrangement also facilitates the measurement of the analyte, as the analysis device 22 is not affected by the coupling medium and may directly sense body fluid emerging from the body surface 20.
  • a third embodiment is illustrated in Figure 4.
  • Two or more ultrasound sources 12 are placed on opposite sides of the pressure boundary 16, so that they create a standing wave such as that described in U.S. Patent Application Serial Number not yet available;
  • Atty Docket Number 5867.US.01 filed 2-26-96
  • the reduced pressure source 14 reduces the pressure in the sampling region 18.
  • the combination of the ultrasound enhanced permeability of the skin and the difference in pressure between the tissue and the sampling region 18 causes fluid to exude from the body surface 18.
  • the concentration of the analyte of interest may then be measured by the analysis device 22.

Abstract

The combined use of an ultrasound source (12) and a pressure-reducing means (14) for the enhancement of transdermal transport of fluids in fluid sampling methods, and for the detection of analytes in a patient's blood.

Description

ENHANCED TRANSDERMAL TRANSPORT OF FLUID
USING VACUUM
Field of the Invention
The present disclosure relates to improved sampling methods for the detection of analytes in a patient's blood. More specifically, the invention is related to the use of vacuum to enhance the transdermal transport of fluids.
Background of the Invention
The ability to accurately measure analytes in the blood, particularly glucose, is important in the management of diseases such as diabetes. Blood glucose levels must be maintained within a narrow range (about 3.5 - 6.5 mM). Glucose levels lower than this range (hypoglycemia) may lead to mental confusion, coma, or death. High glucose levels (hyperglycemia) cause excessive thirst and frequent urination. Sustained hyperglycemia has been linked to several of the complications of diabetes, such as kidney damage, neural damage, and blindness.
Blood glucose levels are maintained in many diabetics with routine injections of insulin. Unlike the normal functioning of the body's glucose control systems, injections of insulin incorporate no feedback mechanisms. Controlling glucose levels therefore requires continuous or frequent measurements of blood glucose concentration in order to determine the proper amount and frequency of insulin injections.
Conventional glucose measurement techniques require lancing of a convenient part of the body (normally a fingertip) with a lancet, milking the finger to produce a drop of blood at the impalement site, and depositing the drop of blood on a measurement device (such as an analysis strip). This lancing of the finger, at typical measurement frequencies of two to four times a day, is both painful and messy for the patient. The pain and inconvenience has additional and more serious implications of noncompliance, in that many patients will not maintain the recommended regimen of blood glucose measurement and thereby run the risk of improper glucose levels and consequent harmful effects. In short, the inherent limitations of conventional blood glucose measurement techniques mean that patients either suffer this pain and inconvenience or neglect glucose monitoring and suffer the adverse physiological effects of improper glucose control. There is a clear need for a glucose measurement technique that minimizes or eliminates pain and inconvenience to the patient.
Devices have been described which use a pump to draw body fluid from the patient to a glucose detector or other analytical instrument. For example, US Patent 5,161 ,532 uses a pump to draw interstitial fluid from the skin to an integral glucose sensor. This system requires a pump capable of creating suction at a level of about 200-400 mmHg. EP Publication 0 595 237 discloses an analytical device for measuring blood constituents such as glucose, which also requires a suction pump capable of creating suction at a level of about 400 mmHg. Body fluid is also sampled through the skin with a suction pump in EP Publication 0 513 789.
In addition, devices have been described which use the local application of ultrasound to increase the permeability of the skin. Ultrasound is believed to disrupt the lipid layers between the keratinocytes in the stratum corneum, thereby increasing the permeability of the skin (Mitragotri et al, J. Pharm Sci 84 : 697-706, 1995). US Patents 4,767,402, 4,780,212, 5, 1 15,805, and 5,421 ,816 discuss the application of frequency and/or modulation of ultrasound to increase the permeability of skin for the purposes of drug delivery. There remains a need for improved devices and methods for the application of a static pressure gradient to increase the effectiveness of ultrasound enhanced permeability, particularly with the objective of enabling speed of extraction while minimizing tissue damage, better control of rates of extraction, and rapid and minimally invasive sampling of body analytes such as glucose.
Brief Description of the Drawings
Figure 1 shows one embodiment of the invention. Figure 2 shows an additional embodiment of the invention. Figure 3 shows an additional embodiment of the invention.
Figure 4 shows an additional embodiment of the invention. Summary of the Invention
The present invention provides a process of sampling extracellular fluid from the skin of an animal wherein ultrasound is applied to a region of the skin, reduced pressure is applied to the same vicinity of the skin and any fluid which exudes the skin is collected. The application of ultrasound and reduced pressure may be performed either sequentially or simultaneously. A preferred source of ultrasound is a standing wave. A preferred analyte is glucose. The present invention also provides a device for the transdermal sampling of extracellular fluid comprising a means for generating an ultrasonic wave through skin of an animal, means for applying reduced pressure to the external surface of the skin in the vicinity of the ultrasonic wave, and means for collecting fluid that transudates the skin. A preferred device utilizes an ultrasonic standing wave and incorporates an analysis element for the analysis of the fluid collected. A preferred analyte for collection by the device of the invention is glucose.
The present invention also provides an improved apparatus for the sampling of extracellular fluid across the skin of animal comprising the application of reduced pressure to the external surface of the skin in the vicinity of the ultrasonic wave.
Detailed Description of the Invention The term "analyte" means any chemical or elemental compound of clinical and/or medical, environmental, or industrial significance and for which quantitative or qualitative measurements may be desired. Examples of specific analytes are well known and include analytes of clinical significance such as glucose, hemoglobin, lipids, cholesterol, proteins, etc. Other analytes will be readily apparent to those skilled in the art. A preferred biological compound is glucose. The present disclosure provides an apparatus and method for enhancing the transdermal transport of analytes. As illustrated in Figure 1 , an apparatus of the invention generally consists of a sampling device 10 comprising a ultrasonic source 12, a pressure reducing source 14, a pressure boundary 16 which, together with a surface 20 of a body part, contains a sampling region 18, and an analysis device 22. Any ultrasonic source 12 is suitable for use in the present invention. Preferably, the source is an ultrasonic transducer capable of generating ultrasonic energy at a frequency range suitable for optimum extraction of glucose, e.g., 20 KHz to 1 MHz. The pressure reducing source 14 is capable of reducing pressure in the sampling region 18 to an absolute pressure of about 400 mmHg; a vacuum pump is preferred. In one embodiment, the pump is powered by normal movements, such as the self-actuated pump described in U.S. Patent Application Serial Number (not yet available; Atty Docket Number 5845.US.01 , filed 12- 18-95). The pressure boundary 16 maintains a pneumatic seal against the surface 20 of the body, and may be any of a variety of well known materials suitable for this purpose, e.g., adhesive tape or an elastomeric ring. In those embodiments where analysis of analyte in sampling region 18 is provided, analysis of collected sample is provided by analysis element 22 located adjacent or, as shown in Figure 1 , in contact with sampling region 18. Analysis element 22 is used to determine the presence or amount of at least one analyte of interest and the particular features of analysis element 22 are not critical to the invention. Thus, any analyte detection method, sensor, or system suitable for use with the analyte of interest, for example optical or electrochemical sensors known in the art, may be used in analysis element 22. An example of a suitable analysis device is an interference-free biosensor such as that described in U.S. Patent Application Serial Number not yet available; Atty Docket Number 5843.US.01 , filed 12- 18-95).
The operation of a particular embodiment of the invention may be understood with reference to Figure 2. The ultrasound source 12 generates ultrasonic energy directed at the body surface 20. The transmission of this ultrasonic energy may be facilitated by the use of a coupling medium (such as a gel) within the sampling region 18. The interaction of the ultrasonic energy with the body surface 20 increases the permeability of the skin at the body surface as described in current scientific literature (Mitragotri et al, J. Pharm. Sci. 84:697-706, 1995). The pressure reducing source 14 reduces the pressure in the sampling region 18 by removing air within the region 18. Note that the presence of a coupling medium within the region 18 should not affect the ability of the pressure reducing source 14 to reduce the pressure within the region 18, and may in fact facilitate the pressure reduction by assisting in maintaining a seal between the pressure boundary 16 and the body surface 20. Any coupling medium should as well not interfere with the operation of the analysis device 22. The combination of the enhanced permeability of the skin due to the ultrasonic energy and the pressure difference between the tissue and the sampling region will cause the enhanced flow of body fluid through the body surface 20 into the sampling region, where the concentration of the analyte is measured by the analysis device 22.
A second embodiment of the invention is illustrated in Figure 3. In this embodiment pressure reducing source 14 is in vacuum connection with the pressure boundary 16 and the ultrasound source 12 and the analysis device 22 are contained within the sampling region 18. Such an arrangement facilitates ultrasound transmission, as the ultrasound source 12 may be directly coupled to the body surface 20, if necessary with the local application of a coupling medium such as a gel. This arrangement also facilitates the measurement of the analyte, as the analysis device 22 is not affected by the coupling medium and may directly sense body fluid emerging from the body surface 20.
A third embodiment is illustrated in Figure 4. Two or more ultrasound sources 12 are placed on opposite sides of the pressure boundary 16, so that they create a standing wave such as that described in U.S. Patent Application Serial Number not yet available;
Atty Docket Number 5867.US.01 , filed 2-26-96) in the body surface 20 adjacent to the sampling region 18. The reduced pressure source 14 reduces the pressure in the sampling region 18. The combination of the ultrasound enhanced permeability of the skin and the difference in pressure between the tissue and the sampling region 18 causes fluid to exude from the body surface 18. The concentration of the analyte of interest may then be measured by the analysis device 22.
All of the references cited in this application are incorporated by reference. The present invention has been described with reference to preferred and/or alternate embodiments. One of skill in the art will readily appreciate that changes, alterations or modifications can be made to these embodiments without departing from the true scope and spirit of the invention.

Claims

CLAIMSWe Claim:
1 . A process of sampling extracellular fluid from the skin of an animal comprising: a ) applying ultrasound to a region of the skin, b ) applying reduced pressure to the defined region of the skin, and c) collecting fluid transudate; wherein steps (a) and (b) may be performed either sequentially or simultaneously.
2. The process of Claim 1 wherein the ultrasound is a standing wave.
3. The process of Claim 1 further comprising the step of analyzing the transudate for the presence or amount of an analyte.
4. The process of Claim 3 wherein the analysis is performed by optical or electrochemical methods.
5. The process of Claim 4 wherein the analyte is glucose.
6. An apparatus for the transdermal sampling of extracellular fluid comprising: a ) means for generating an ultrasonic wave through skin of an animal; b ) means for applying reduced pressure to the external surface of the skin in the vicinity of the ultrasonic wave; an d c) means for collecting fluid that transudates the skin.
7. The apparatus of Claim 7 wherein the ultrasonic wave is a standing wave.
8. The apparatus of Claim 6 further comprising an analysis element to analyze the transudate for the presence or amount of an analyte.
9. The apparatus of Claim 8 wherein the analysis is performed by optical or electrochemical methods.
1 0. The apparatus of Claim 9 wherein the analyte is glucose.
1 1 . In an apparatus for the sampling of extracellular fluid across the skin of animal comprising: a ) an ultrasound transducer directed to apply an ultrasonic wave to the skin surface; b ) an absorbent material positioned to absorb fluid that transudates the skin; and c) means for analyzing the fluid for the presence or amount of analyte; the improvement comprising the application of reduced pressure to the external surface of the skin in the vicinity of the ultrasonic wave.
PCT/US1997/002483 1996-02-23 1997-02-14 Enhanced transdermal transport of fluid using vacuum WO1997030628A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE69728525T DE69728525T2 (en) 1996-02-23 1997-02-14 BY VACUUM IMPROVED TRANSDERMALER LIQUID TRANSPORT
AT97906647T ATE263505T1 (en) 1996-02-23 1997-02-14 VACUUM-ENHANCED TRANSDERMAL FLUID TRANSPORT
JP9530273A JP2000505334A (en) 1996-02-23 1997-02-14 Improved transdermal transport of fluids using vacuum
EP97906647A EP0886488B1 (en) 1996-02-23 1997-02-14 Enhanced transdermal transport of fluid using vacuum

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/606,506 1996-02-23
US08/606,506 US6009343A (en) 1996-02-23 1996-02-23 Enhanced transdermal transport of fluid using vacuum

Publications (1)

Publication Number Publication Date
WO1997030628A1 true WO1997030628A1 (en) 1997-08-28

Family

ID=24428251

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/002483 WO1997030628A1 (en) 1996-02-23 1997-02-14 Enhanced transdermal transport of fluid using vacuum

Country Status (8)

Country Link
US (1) US6009343A (en)
EP (1) EP0886488B1 (en)
JP (1) JP2000505334A (en)
AT (1) ATE263505T1 (en)
CA (1) CA2245710A1 (en)
DE (1) DE69728525T2 (en)
ES (1) ES2221953T3 (en)
WO (1) WO1997030628A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000014535A1 (en) * 1998-09-09 2000-03-16 Amira Medical Interstitial fluid methods and devices for determination of an analyte in the body
US6251083B1 (en) 1999-09-07 2001-06-26 Amira Medical Interstitial fluid methods and devices for determination of an analyte in the body
WO2001070330A3 (en) * 2000-03-17 2002-05-23 Sontra Medical Inc Non-invasive body fluid sampling and analysis
US7857759B2 (en) 2003-03-26 2010-12-28 Sysmex Corporation Extraction device, analyzer, extraction method, and analysis method
US8870810B2 (en) 1998-12-18 2014-10-28 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
US10610135B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10813577B2 (en) 2005-06-21 2020-10-27 Dexcom, Inc. Analyte sensor

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19800416C2 (en) * 1998-01-08 2002-09-19 Storz Karl Gmbh & Co Kg Device for the treatment of body tissue, in particular soft tissue close to the surface, by means of ultrasound
US8287483B2 (en) 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US7066884B2 (en) * 1998-01-08 2006-06-27 Sontra Medical, Inc. System, method, and device for non-invasive body fluid sampling and analysis
DE69937738D1 (en) * 1998-07-21 2008-01-24 Altea Therapeutics Corp METHOD AND DEVICE FOR THE CONTINUOUS MONITORING OF AN ANALYTE
AU2001288668A1 (en) * 2000-08-31 2002-03-13 Advanced Sensor Technologies Micro-fluidic system
NZ512367A (en) * 2001-06-14 2005-05-27 Horticulture & Food Res Inst Non-invasive transudate extraction
US20040094733A1 (en) * 2001-08-31 2004-05-20 Hower Robert W. Micro-fluidic system
JP4599872B2 (en) * 2004-03-31 2010-12-15 パナソニック電工株式会社 Blood glucose meter
US20060094945A1 (en) 2004-10-28 2006-05-04 Sontra Medical Corporation System and method for analyte sampling and analysis
CA2584699C (en) 2004-10-28 2015-12-08 Sontra Medical Corporation System and method for analyte sampling and analysis with hydrogel
US8812071B2 (en) 2007-03-07 2014-08-19 Echo Therapeutics, Inc. Transdermal analyte monitoring systems and methods for analyte detection
US8386027B2 (en) 2007-04-27 2013-02-26 Echo Therapeutics, Inc. Skin permeation device for analyte sensing or transdermal drug delivery
WO2008144274A2 (en) * 2007-05-14 2008-11-27 Sono Esthetx, Inc. Method, system, and apparatus for line-focused ultrasound therapy
JP2010266203A (en) * 2008-05-20 2010-11-25 Sony Corp Method and device for acquisition of biological information, and method and device for measurement of physiologically active substance
EP3278728A1 (en) * 2016-08-01 2018-02-07 Nokia Technologies Oy An apparatus, system and method for detecting analytes from a user's skin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5161532A (en) * 1990-04-19 1992-11-10 Teknekron Sensor Development Corporation Integral interstitial fluid sensor
US5171215A (en) * 1991-08-22 1992-12-15 Flanagan Dennis F Endermic method and apparatus
US5458140A (en) * 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767402A (en) * 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4780212A (en) * 1987-07-31 1988-10-25 Massachusetts Institute Of Technology Ultrasound enchancement of membrane permeability
US5115805A (en) * 1990-02-23 1992-05-26 Cygnus Therapeutic Systems Ultrasound-enhanced delivery of materials into and through the skin
JP2684871B2 (en) * 1991-05-16 1997-12-03 日本電気株式会社 Body fluid component measuring method and measuring device
US5421816A (en) * 1992-10-14 1995-06-06 Endodermic Medical Technologies Company Ultrasonic transdermal drug delivery system
JPH0824680B2 (en) * 1992-10-26 1996-03-13 日本電気株式会社 Suction leachate sampling device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5161532A (en) * 1990-04-19 1992-11-10 Teknekron Sensor Development Corporation Integral interstitial fluid sensor
US5171215A (en) * 1991-08-22 1992-12-15 Flanagan Dennis F Endermic method and apparatus
US5458140A (en) * 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000014535A1 (en) * 1998-09-09 2000-03-16 Amira Medical Interstitial fluid methods and devices for determination of an analyte in the body
US8870810B2 (en) 1998-12-18 2014-10-28 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US6251083B1 (en) 1999-09-07 2001-06-26 Amira Medical Interstitial fluid methods and devices for determination of an analyte in the body
WO2001070330A3 (en) * 2000-03-17 2002-05-23 Sontra Medical Inc Non-invasive body fluid sampling and analysis
US7857759B2 (en) 2003-03-26 2010-12-28 Sysmex Corporation Extraction device, analyzer, extraction method, and analysis method
US10993641B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
US10722152B2 (en) 2004-07-13 2020-07-28 Dexcom, Inc. Analyte sensor
US10524703B2 (en) 2004-07-13 2020-01-07 Dexcom, Inc. Transcutaneous analyte sensor
US11883164B2 (en) 2004-07-13 2024-01-30 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11064917B2 (en) 2004-07-13 2021-07-20 Dexcom, Inc. Analyte sensor
US11045120B2 (en) 2004-07-13 2021-06-29 Dexcom, Inc. Analyte sensor
US11026605B1 (en) 2004-07-13 2021-06-08 Dexcom, Inc. Analyte sensor
US10918314B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US10709363B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US10709362B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US10993642B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
US10980452B2 (en) 2004-07-13 2021-04-20 Dexcom, Inc. Analyte sensor
US10799158B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US10799159B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US10932700B2 (en) 2004-07-13 2021-03-02 Dexcom, Inc. Analyte sensor
US10813576B2 (en) 2004-07-13 2020-10-27 Dexcom, Inc. Analyte sensor
US10827956B2 (en) 2004-07-13 2020-11-10 Dexcom, Inc. Analyte sensor
US9414777B2 (en) 2004-07-13 2016-08-16 Dexcom, Inc. Transcutaneous analyte sensor
US10918315B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US10918313B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US10918318B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10743801B2 (en) 2005-03-10 2020-08-18 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918317B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10898114B2 (en) 2005-03-10 2021-01-26 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10856787B2 (en) 2005-03-10 2020-12-08 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10925524B2 (en) 2005-03-10 2021-02-23 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610135B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918316B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10716498B2 (en) 2005-03-10 2020-07-21 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10709364B2 (en) 2005-03-10 2020-07-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11000213B2 (en) 2005-03-10 2021-05-11 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10617336B2 (en) 2005-03-10 2020-04-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610136B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11051726B2 (en) 2005-03-10 2021-07-06 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610137B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10813577B2 (en) 2005-06-21 2020-10-27 Dexcom, Inc. Analyte sensor

Also Published As

Publication number Publication date
DE69728525D1 (en) 2004-05-13
US6009343A (en) 1999-12-28
CA2245710A1 (en) 1997-08-28
JP2000505334A (en) 2000-05-09
DE69728525T2 (en) 2005-04-07
ES2221953T3 (en) 2005-01-16
EP0886488B1 (en) 2004-04-07
ATE263505T1 (en) 2004-04-15
EP0886488A1 (en) 1998-12-30

Similar Documents

Publication Publication Date Title
US6009343A (en) Enhanced transdermal transport of fluid using vacuum
US7625457B2 (en) Dual blade lancing test strip
US7766845B2 (en) Disposable lancet and lancing cap combination for increased hygiene
US7476202B2 (en) Sampling devices and methods utilizing a horizontal capillary test strip
US20090270704A1 (en) Patches, systems, and methods for non-invasive glucose measurement
US6990367B2 (en) Percutaneous biological fluid sampling and analyte measurement devices and methods
US9451914B2 (en) Integrated needle and test strip assembly and method of use
JP2005501591A (en) Exudation method and structure for use in sampling body fluid
JP2004000598A (en) Apparatus and method for accessing and analyzing physiological fluid
JP2003153885A (en) Lancet and analytical apparatus having test element
EP1359841A1 (en) System, for monitoring the concentration of analytes in body fluids
EP2571425B1 (en) Transdermal device
Vranić et al. Microneedle-based sensor systems for real-time continuous transdermal monitoring of analytes in body fluids
WO2017100480A1 (en) Apparatus and method for detecting and/or monitoring one or more compounds in blood
EP1416852A1 (en) Sampling devices and methods for bodily fluids
CN108982604A (en) The portable monitoring system of analyte in a kind of dynamic METHOD FOR CONTINUOUS DETERMINATION body fluid
US20160113561A1 (en) Apparatus and method for detecting and/or monitoring one or more compounds in blood
Sheikh et al. Optical Detection of Lithium Therapeutic Levels in Porcine Interstitial Fluid Collected Using a Hollow Microneedle
Bansod et al. Comparative study of current approaches for minimally invasive and non-invasive blood glucose monitoring
JPH0197436A (en) Apparatus for measuring substance relating to living body

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2245710

Country of ref document: CA

Ref country code: CA

Ref document number: 2245710

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997906647

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997906647

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997906647

Country of ref document: EP